Scythian Biosciences extends letter of intent to buy medical cannabis company
Insight Weekly: Recession risk persists; Banks pull back from crypto; 2022 laggard stocks rally
Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage
Insight Weekly: Inflation eases; bank M&A slows; top companies boost market share
Insight Weekly: PE firms shift strategies; bank earnings kick off; bankruptcies plummet
Scythian Biosciences Corp. said it extended the previously announced letter of intent to buy MMJ International Investments Inc., a company pursuing medical cannabis opportunities in South America.
The companies now have until April 30 to negotiate a definitive deal, as opposed to March 31 previously.
Scythian, a Canadian medical cannabis company, added that its COO David Schrader will step down on March 31.
